NovaHep is raising new equity

Having successfully reached significant milestones and proof of concept, NovaHep  is currently raising new equity to finance GMP-adaptation and start the initial clinical trial related to its tissue-engineered vein for surgical treatment of chronic venous insufficiency (CVI). The pipeline further consists of other tissues such as arteries and valves and the company is even researching and developing tissue-engineered whole organs such as kidneys and hearts. NovaHep faces a great global potential with short expected time to market.

For introductory material about NovaHep and the technology. Additional information can be found here, or at